Obiltoxaximab (Anthim) Market Report 2026

Obiltoxaximab (Anthim) Market Overview

• The Obiltoxaximab (Anthim) market growth in the historic period has been driven by heightened biodefense preparedness initiatives, government investment in anthrax countermeasures • Market expansion is supported by expansion of national biodefense stockpiles, rising investments in next-generation antitoxin therapies • Growth Driver: Rising Zoonotic Disease Incidence Fuels Demand For The Market • North America was the largest region in 2025.

What Is Covered Under Obiltoxaximab (Anthim) Market?

Obiltoxaximab (Anthim) is a monoclonal antibody used to treat inhalational anthrax caused by Bacillus anthracis. It works by binding to the protective antigen component of the anthrax toxin, preventing it from entering cells and causing damage. Obiltoxaximab is typically administered alongside appropriate antibacterial drugs and is approved for use in adults and children. The main types of obiltoxaximab (anthim) distribution channels include distributors and online pharmacies. Distributors are entities that supply products, like pharmaceuticals, from manufacturers to retailers or healthcare providers. It is applied for bioterrorism treatment, inhalational anthrax, cutaneous anthrax, and gastrointestinal anthrax and is used by hospitals and outpatient clinics.

What Is The Obiltoxaximab (Anthim) Market Growth Forecast?

The growth in the forecast period can be attributed to expansion of national biodefense stockpiles, rising investments in next-generation antitoxin therapies, increased cross-border health security collaboration, growing focus on rapid deployment medical countermeasures, advancement in monoclonal antibody production technologies. Major trends in the forecast period include increasing strategic stockpiling of biodefense therapeutics, rising focus on rapid-response monoclonal antibodies, expansion of government-backed procurement programs, improved emergency preparedness frameworks, enhanced cold-chain distribution capabilities.

Global Obiltoxaximab (Anthim) Market Segmentation

1) By Distribution Channel: Distributors, Online Pharmacies 2) By Application: Bioterrorism Treatment, Inhalational Anthrax, Cutaneous Anthrax, Gastrointestinal Anthrax 3) By End User: Hospitals, Outpatient Clinics

What Are The Drivers Of The Obiltoxaximab (Anthim) Market?

The rising incidence of zoonotic diseases is expected to drive the growth of the obiltoxaximab (anthim) market going forward. Zoonotic diseases are infections transmitted from animals to humans, either directly or through contact with animal products or vectors like insects. The incidence of zoonotic diseases is rising due to factors such as increasing human-wildlife contact, urbanization, climate change, and global travel, which facilitate the spread of infections from animals to humans. The rising incidence of zoonotic diseases highlights the need for effective treatments such as obiltoxaximab (anthim), which targets anthrax, a deadly zoonotic infection, providing critical protection in response to increasing outbreaks. For instance, in December 2023, according to the World Health Organization, a Switzerland-based intergovernmental organization, 684 suspected cases of anthrax have been reported in nine out of ten provinces in Zambia, representing a severe outbreak. With four confirmed deaths as a result of the epidemic, the case mortality ratio is 0.6%. Therefore, the rising incidence of zoonotic diseases will drive the obiltoxaximab (anthim) industry. The rising healthcare expenditure is expected to propel the growth of the obiltoxaximab (anthim) market going forward. Healthcare expenditure is the total spending on medical services, treatments, hospital care, pharmaceuticals, and other health-related services. Increasing healthcare expenditure is driven by an aging population, the rise of chronic diseases, and higher demand for healthcare services. Increased healthcare expenditure enhances access to advanced treatments such as obiltoxaximab/anthim by funding research, procurement, and deployment of critical therapies for managing zoonotic diseases and bioterrorism threats. For instance, in November 2025, according to Organisation for Economic Co-operation and Development, a US-based intergovernmental organization, reported that in 2024, OECD countries are estimated to have allocated around 9.3% of their GDP to health on average. Therefore, the rising healthcare expenditure is driving the growth of the obiltoxaximab (anthim) industry. The increasing biodefense budgets are expected to drive the growth of the obiltoxaximab (Anthim) market in the coming years. Biodefense budgets refer to the financial allocations by governments and international organizations for preparedness, prevention, and response to biological threats, including bioterrorism and emerging infectious diseases. Obiltoxaximab (Anthim) strengthens national biodefense strategies by providing a targeted treatment against inhalational anthrax, enhancing preparedness for bioterrorism threats. For instance, in July 2023, the Council on Strategic Risks, a US-based nonpartisan research and policy organization, reported that the FY2024 budget proposes $400 million in new discretionary funding for BARDA/ASPR’s pandemic and biodefense preparedness efforts. Therefore, increasing biodefense budgets is driving the growth of the obiltoxaximab (anthim) industry.

Key Players In The Global Obiltoxaximab (Anthim) Market

Major companies operating in the obiltoxaximab (anthim) market are Scorpius Holdings Inc.

Regional Insights

North America was the largest region in the obiltoxaximab (anthim) market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Obiltoxaximab (Anthim) Market?

The obiltoxaximab (anthim) market consists of sales of anthrax therapeutics, infectious disease treatments, emergency biodefense products and intravenous (iv) infusion kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Obiltoxaximab (Anthim) Market Report 2026?

The obiltoxaximab (anthim) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the obiltoxaximab (anthim) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.